Bioassay position open at Wuxi Biologics! Serve as a technique lead in a world-class team. Monitor assay performance, provide guidance to investigation, communicate with global partners, and many more exciting opportunities to come! Position located at Wuxi, China.
Ph.D. or M.S.+2y. Immunology, cell biology, biochemistry and related majors required. GMP experience preferred.
--- WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-endsolutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients. With total estimated capacity for biopharmaceutical production planned in China, Ireland, the U.S., Germany, and Singapore exceeding 280,000 liters after 2023, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network. As of June 30, 2020, there were a total of 286 integrated projects , including 141 projects in pre-clinical development stage, 125 projects in early-phase (phase I and II)clinical development, 19 projects in late-phase (phase III) development and one project in commercial manufacturing.
Bioassay position open at Wuxi Biologics! Serve as a technique lead in a
world-class team. Monitor assay performance, provide guidance to
investigation, communicate with global partners, and many more exciting
opportunities to come! Position located at Wuxi, China.
Ph.D. or M.S.+2y.
Immunology, cell biology, biochemistry and related majors required.
GMP experience preferred.
Contact [email protected] if you are interested.
---
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a
leading global open-access biologics technology platform offering end-to-endsolutions to empower organizations to discover, develop, and manufacture
biologics from concept to commercial manufacturing. The company’s history
and achievements demonstrate its commitment to providing a truly ONE-stop
service offering and strong value proposition to its global clients. With
total estimated capacity for biopharmaceutical production planned in China,
Ireland, the U.S., Germany, and Singapore exceeding 280,000 liters after
2023, WuXi Biologics will provide its biomanufacturing partners with a
robust and premier-quality global supply chain network. As of June 30, 2020, there were a total of 286 integrated projects , including 141 projects in
pre-clinical development stage, 125 projects in early-phase (phase I and II)clinical development, 19 projects in late-phase (phase III) development and
one project in commercial manufacturing.